{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T03:14:57Z","timestamp":1788578097077,"version":"build-2803163510"},"reference-count":24,"publisher":"Elsevier BV","issue":"10520","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/s0140-6736(25)02114-2","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T19:21:21Z","timestamp":1762888881000},"page":"2644-2655","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study"],"prefix":"10.1016","volume":"406","author":[{"given":"Mazen","family":"Noureddin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen A","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Loomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naim","family":"Alkhouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naga","family":"Chalasani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Y","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaheen","family":"Tomah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio A","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Urbina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J","family":"Suschak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randy","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozioma","family":"Odili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephine","family":"Keeton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Neff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Mena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M Scot","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah K","family":"Browne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M Scott","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/S0140-6736(25)02114-2_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2025.02.006","article-title":"High global prevalence of steatotic liver disease and associated subtypes: a meta-analysis","author":"Ho","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"suppl","key":"10.1016\/S0140-6736(25)02114-2_bib2","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","article-title":"Epidemiology of metabolic dysfunction-associated steatotic liver disease","volume":"31","author":"Younossi","year":"2025","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/S0140-6736(25)02114-2_bib3","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.metabol.2018.11.014","article-title":"Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics","volume":"92","author":"Polyzos","year":"2019","journal-title":"Metabolism"},{"key":"10.1016\/S0140-6736(25)02114-2_bib4","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMra1503519","article-title":"Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis","volume":"377","author":"Diehl","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(25)02114-2_bib5","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","article-title":"Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies","volume":"13","author":"Singh","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/S0140-6736(25)02114-2_bib6","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1016\/j.cgh.2024.03.006","article-title":"The global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among patients with type 2 diabetes","volume":"22","author":"Younossi","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/S0140-6736(25)02114-2_bib7","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(25)02114-2_bib8","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(25)02114-2_bib9","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/13543784.2025.2473062","article-title":"The pleiotropic effects of glucagon-like peptide-1 receptor agonists in patients with metabolic dysfunction-associated steatohepatitis: a review for gastroenterologists","volume":"34","author":"Alkhouri","year":"2025","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/S0140-6736(25)02114-2_bib10","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa2401755","article-title":"A phase 2 randomized trial of survodutide in MASH and fibrosis","volume":"391","author":"Sanyal","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(25)02114-2_bib11","article-title":"Design and characterization of a surfactant-conjugated, long-acting, balanced GLP-1\/glucagon receptor dual agonist","volume":"113","author":"Nestor","year":"2021","journal-title":"Pept Sci (Hoboken)"},{"key":"10.1016\/S0140-6736(25)02114-2_bib12","first-page":"E981","article-title":"Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans","volume":"273","author":"Nauck","year":"1997","journal-title":"Am J Physiol"},{"key":"10.1016\/S0140-6736(25)02114-2_bib13","article-title":"Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: a randomized, controlled clinical trial","volume":"7","author":"Browne","year":"2025","journal-title":"JHEP Rep Innov Hepatol"},{"key":"10.1016\/S0140-6736(25)02114-2_bib14","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/S0140-6736(25)02114-2_bib15","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41591-024-03301-2","article-title":"Clinical validation of an AI-based pathology tool for scoring of metabolic dysfunction-associated steatohepatitis","volume":"31","author":"Pulaski","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/S0140-6736(25)02114-2_bib16","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(25)02114-2_bib17","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","article-title":"Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/S0140-6736(25)02114-2_bib18","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1111\/apt.16608","article-title":"Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging","volume":"54","author":"Flint","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/S0140-6736(25)02114-2_bib19","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up","volume":"61","author":"Ekstedt","year":"2015","journal-title":"Hepatology"},{"issue":"suppl 1","key":"10.1016\/S0140-6736(25)02114-2_bib20","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/dom.13162","article-title":"A review of GLP-1 receptor agonists: Evolution and advancement, through the lens of randomised controlled trials","volume":"20","author":"Aroda","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/S0140-6736(25)02114-2_bib21","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1007\/s12325-020-01548-y","article-title":"Pharmacokinetics, safety and tolerability of once-weekly subcutaneous semaglutide in healthy Chinese Subjects: a double-blind, phase 1, randomized controlled trial","volume":"38","author":"Shi","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/S0140-6736(25)02114-2_bib22","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.jhep.2024.06.003","article-title":"Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon\/glucagon-like peptide-1 receptor dual agonist, in cirrhosis","volume":"81","author":"Lawitz","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/S0140-6736(25)02114-2_bib23","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.57349","article-title":"Discontinuation and reinitiation of dual-labeled glp-1 receptor agonists among US Adults with overweight or obesity","volume":"8","author":"Rodriguez","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/S0140-6736(25)02114-2_bib24","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.2337\/dc24-1082","article-title":"Real-world use of semaglutide for weight management: patient characteristics and dose titration\u2014A Danish cohort study","volume":"47","author":"Ladebo","year":"2024","journal-title":"Diabetes Care"}],"container-title":["The Lancet"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0140673625021142?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0140673625021142?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:36:26Z","timestamp":1764894986000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0140673625021142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":24,"journal-issue":{"issue":"10520","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0140673625021142"],"URL":"https:\/\/doi.org\/10.1016\/s0140-6736(25)02114-2","relation":{},"ISSN":["0140-6736"],"issn-type":[{"value":"0140-6736","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study","name":"articletitle","label":"Article Title"},{"value":"The Lancet","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S0140-6736(25)02114-2","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}